Financial Perspectives’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.4K Hold
350
0.01% 402
2026
Q1
$27.7K Hold
350
0.01% 397
2025
Q4
$28.8K Hold
350
0.01% 387
2025
Q3
$24.5K Hold
350
0.01% 402
2025
Q2
$22.4K Hold
350
0.01% 403
2025
Q1
$22.2K Hold
350
0.01% 400
2024
Q4
$23.3K Hold
350
0.01% 392
2024
Q3
$24.4K Hold
350
0.01% 366
2024
Q2
$22.7K Hold
350
0.01% 366
2024
Q1
$22.6K Hold
350
0.01% 365
2023
Q4
$23K Hold
350
0.01% 365
2023
Q3
$20K Hold
350
0.01% 361
2023
Q2
$21.4K Hold
350
0.01% 358
2023
Q1
$22K Hold
350
0.01% 348
2022
Q4
$22.2K Hold
350
0.01% 342
2022
Q3
$20.6K Hold
350
0.01% 343
2022
Q2
$20.2K Hold
350
0.01% 347
2022
Q1
$21.7K Hold
350
0.01% 357
2021
Q4
$24.9K Hold
350
0.01% 327
2021
Q3
$26.2K Hold
350
0.01% 326
2021
Q2
$27.1K Hold
350
0.01% 342
2021
Q1
$25.8K Hold
350
0.01% 326
2020
Q4
$24.5K Hold
350
0.01% 311
2020
Q3
$19.8K Hold
350
0.01% 292
2020
Q2
$20.4K Hold
350
0.01% 272
2020
Q1
$16.3K Hold
350
0.01% 266
2019
Q4
$19.5K Buy
+350
New +$18.2K 0.01% 260

Other funds holding PBE

Financial Perspectives's PBE Position: Q2 2026 in Review

Financial Perspectives held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 350 shares worth $31.4K. The position accounts for 0.01% of the portfolio, ranked #402.

Financial Perspectives first reported a position in PBE in Q4 2019 and has held it in 27 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • Financial Perspectives held 350 shares of Invesco Biotechnology & Genome ETF worth $31.4K as of Q2 2026.
  • Financial Perspectives left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
  • Invesco Biotechnology & Genome ETF made up 0.01% of Financial Perspectives's portfolio in Q2 2026, its #402 holding.
  • Financial Perspectives first reported a position in Invesco Biotechnology & Genome ETF in Q4 2019 and has held it in 27 quarters since.
  • 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.